Healthy
Conditions
Brief summary
The purpose of the study is to characterize the pharmacokinetics of single and multiple doses of JNJ-70033093 (BMS-986177) in healthy Chinese participants.
Interventions
DRUGJNJ-70033093
JNJ-70033093 capsule will be administered orally as per assigned treatment regimen.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy on the basis of physical examination, medical history, vital signs, Electrocardiogram (ECG), and the results of serum biochemistry, blood coagulation and hematology test and a urinalysis performed at screening. If there are abnormalities, investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator * Must sign an Informed consent Form (ICF) indicating that they understand the purpose of, and procedures required for the study and is willing to participate in the study * If a woman, except for postmenopausal women, must have a negative highly sensitive serum (beta human chorionic gonadotropin \[beta hCG\]) at screening and urine (beta-hCG) pregnancy test on Day -1 * Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for subject participating in clinical studies * Before randomization, a woman must be either not of childbearing potential; of childbearing potential and practicing a highly effective method of contraception and agrees to remain on a highly effective method throughout the study and for at least 34 days after the last dose of study drug; women must have no history of excessive menstrual bleeding or hemorrhage following pregnancy delivery
Exclusion criteria
* If a woman, pregnant, breast-feeding or planning to become pregnant during the study * Participants with current hepatitis B infection (confirmed by hepatitis B surface antigen \[HBsAg\]), or hepatitis C infection (confirmed by hepatitis C virus \[HCV\] antibody), or human immunodeficiency virus type-1 (HIV-1) or HIV-2 infection at study screening * History of, or a reason to believe a subject has a history of, drug or alcohol abuse within the past 1 year, which in the Investigator's opinion would compromise subject's safety and/or compliance with the study procedures * History of any significant drug allergy (such as anaphylaxis or hepatotoxicity) and known allergy to the study drug or any of the excipients of the formulation * Preplanned surgery or procedures that would interfere with the conduct of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cohort A and D: Plasma Concentration of JNJ-70033093 After Single Dose Administration | Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B) | Plasma concentration of JNJ-70033093 after single dose administration will be analyzed. |
| Cohort A, B, C and D: Plasma Concentration of JNJ-70033093 After Multiple Dose Administration | Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B) | Observed plasma concentration of JNJ-70033093 after multiple dose administration will be analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Vital Signs Abnormalities | Up to 54 Days | Number of participants with vital sign abnormalities (such as, blood pressure, pulse, respiratory rate, and temperature) will be assessed. |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Up to 54 Days | Number of participants who experience at least 1 occurrence of each treatment emergent adverse event (TEAE) will be assessed. |
| Percentage Change From Baseline in FXI Clotting Activity | Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B) | Percentage change from baseline in FXI clotting activity will be measured using a modified aPTT assay. |
| Change From Baseline in Activated Partial Thromboplastin Time (aPTT) | Up to Day 15 (Cohort A and D) and up to Day 11 (Cohort C and B) | Activated partial thromboplastin time measures the time to clot formation via the intrinsic (contact) and common pathways, and is dependent on activation of contact factors (such as FXI). |
| Number of Participants with Clinical Laboratory Abnormalities | Up to 54 Days | Number of participants with clinical laboratories (such as Hematology, Coagulation, Serum chemistry and urinalysis) abnormalities will be assessed. |
Countries
China
Outcome results
None listed